SITE Centers (US:SITC) GlobeNewswire News Roomยท2024-11-07 13:00Core Insights - Indaptus Therapeutics presented promising safety, pharmacokinetics, and biomarker data for its lead compound Decoy20 at the SITC 2024 annual meeting, based on a Phase 1 clinical trial involving 19 patients [1][2][3] - The trial results indicated that Decoy20, administered intravenously once weekly, primarily resulted in mild to moderate and transient side effects, with a rapid elimination from the bloodstream supporting the company's "pulse" approach [2][3] - One patient with squamous cell carcinoma of the head and neck exhibited "stable disease" at the first imaging scan, indicating no progression of cancer [2] Company Overview - Indaptus Therapeutics focuses on innovative cancer and viral infection treatments, leveraging a patented Decoy platform that activates both innate and adaptive immune responses [4] - The Decoy technology utilizes non-pathogenic Gram-negative bacteria to stimulate immune pathways, aiming for reduced intravenous toxicity while maintaining efficacy [4] - Preclinical studies have shown Decoy candidates' effectiveness against various cancers and chronic viral infections, demonstrating potential for combination therapies with existing treatments [4] Future Directions - The company is expanding its clinical trial to include patients with six different tumor types for weekly dosing and is collaborating with BeiGene to combine Decoy20 with its PD-1 inhibitor, tislelizumab [3] - Management expresses confidence in the Decoy platform's potential and plans to continue sharing positive results while exploring new opportunities [3]